Bio-Techne Corporation (TECH)
After hours:
| Previous Close | 71.05 |
| Open | 71.10 |
| Bid | 71.23 x 100 |
| Ask | 71.31 x 400 |
| Day's Range | 70.61 - 72.41 |
| 52 Week Range | 61.16 - 85.57 |
| Volume | |
| Avg. Volume | 930,704 |
| Market Cap | 11.326B |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | 75.03 |
| EPS (TTM) | 0.95 |
| Earnings Date | Jan 30, 2025 - Feb 03, 2025 |
| Forward Dividend & Yield | 0.32 (0.45%) |
| Ex-Dividend Date | Nov 08, 2024 |
| 1y Target Est | 85.25 |
PR NewswireBIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES
Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates.
- PR Newswire
BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH
Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.
